Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Artigo
|
![]() |
CHARACTERISTICS OF PATIENTS ACHIEVING COMPLETE OR PARTIAL RESPONSE (CR/PR) WITH TAZEMETOSTAT (TAZ) IN WILD‐TYPE RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)Batlevi, C. L. ; Salles, G. ; Tilly, H. ; Chaidos, A. ; McKay, P. ; Phillips, T. ; Assouline, S. ; Campbell, P. ; Ribrag, V. ; Damaj, G. Laurent ; Dickinson, M. ; Jurczak, W. ; Kaźmierczak, M. ; Opat, S. ; Radford, J. R. ; Schmitt, A. ; Rajarethinam, A. ; Shang, G. ; Morschhauser, F.Hematological oncology, 2021-06, Vol.39 (S2) [Periódico revisado por pares]Chichester: Wiley Subscription Services, IncTexto completo disponível |
2 |
Material Type: Artigo
|
![]() |
Analysis of Real‐World Treatment Patterns and Outcomes Among Patients With Relapsed/Refractory Follicular Lymphoma Including POD24 PatientsSehn, L. H. ; Wang, A. ; Yu, J. ; Kamalakar, R. ; Sail, K. ; Sinai, W. ; Arnette, D. ; Yang, S. ; Mutebi, A. ; Navarro, F. R. ; Salles, G.Hematological oncology, 2023-06, Vol.41 (S2), p.373-375 [Periódico revisado por pares]Texto completo disponível |
3 |
Material Type: Artigo
|
![]() |
CAR‐HEMATOTOX: A DISCRIMINATIVE MODEL FOR CAR T‐CELL RELATED HEMATOTOXICITY IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMARejeski, K. ; Perez, A. ; Sesques, P. ; Berger, C. ; Jentzsch, L. ; Mougiakakos, D. ; Frölich, L. ; Ackermann, J. ; Bücklein, V. ; Blumenberg, V. ; Schmidt, C. ; Jallades, L. ; Fehse, B. ; Faul, C. ; Karschnia, P. ; Weigert, O. ; Dreyling, M. ; Hoster, E. ; Locke, F. ; von Bergwelt‐Baildon, M. ; Mackensen, A. ; Bethge, W. ; Ayuk, F. ; Bachy, E. ; Salles, G. ; Jain, M. ; Subklewe, M.Hematological oncology, 2021-06, Vol.39 (S2) [Periódico revisado por pares]Chichester: Wiley Subscription Services, IncTexto completo disponível |
4 |
Material Type: Artigo
|
![]() |
CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE POLARIX STUDYHerrera, A. F. ; Tracy, S. ; Sehn, L. H. ; Jardin, F. ; Lenz, G. ; Trněný, M. ; Salles, G. ; Flowers, C. R. ; Tilly, H. ; Sharman, J. P. ; Friedberg, J. W. ; Balasubramanian, S. ; Raghavan, V. ; Hirata, J. ; Lee, C. ; Jiang, Y. ; Morschhauser, F.Hematological oncology, 2023-06, Vol.41 (S2), p.175-177 [Periódico revisado por pares]Texto completo disponível |
5 |
Material Type: Artigo
|
![]() |
Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND studyDuell, J. ; Abrisqueta, P. ; Andre, M. ; Augustin, M. ; Gaidano, G. ; Barca, E. G. ; Jurczak, W. ; Kalakonda, N. ; Liberati, A. M. ; Maddocks, K. J. ; Menne, T. ; Nagy, Z. ; Tournilhac, O. ; Bakuli, A. ; Amin, A. ; Gurbanov, K. ; Salles, G.Hematological oncology, 2023-06, Vol.41 (S2), p.437-439 [Periódico revisado por pares]Texto completo disponível |
6 |
Material Type: Artigo
|
![]() |
Five‐year subgroup analysis of tafasitamab + lenalidomide from the Phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphomaDuell, J. ; Abrisqueta, P. ; Dreyling, M. ; Gaidano, G. ; Barca, E. G. ; Jurczak, W. ; Maddocks, K. J. ; Menne, T. ; Nagy, Z. ; Tournilhac, O. ; Bakuli, A. ; Amin, A. ; Gurbanov, K. ; Salles, G.Hematological oncology, 2023-06, Vol.41 (S2), p.439-441 [Periódico revisado por pares]Texto completo disponível |
7 |
Material Type: Artigo
|
![]() |
TREATMENT‐DEPENDENCE OF HIGH‐RISK GENE EXPRESSION SIGNATURES IN DE NOVO FOLLICULAR LYMPHOMABolen, C.R. ; Hiddemann, W. ; Marcus, R. ; Herold, M. ; Huet, S. ; Salles, G. ; Mattiello, F. ; Nielsen, T. ; Mir, F. ; Venstrom, J.M. ; Oestergaard, M.Z.Hematological oncology, 2019-06, Vol.37 (S2), p.193-194 [Periódico revisado por pares]Chichester: Wiley Subscription Services, IncTexto completo disponível |
8 |
Material Type: Artigo
|
![]() |
INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMAMorschhauser, F. ; Tilly, H. ; Chaidos, A. ; Phillips, T. ; Ribrag, V. ; Campbell, P. ; Ghandi Laurent, D. ; Jurczak, W. ; McKay, P. ; Opat, S. ; Radford, J. ; Rajarethinam, A. ; Yang, J. ; Howell, H. ; Newberry, K.J. ; Adib, D. ; Salles, G.Hematological oncology, 2019-06, Vol.37 (S2), p.154-156 [Periódico revisado por pares]Chichester: Wiley Subscription Services, IncTexto completo disponível |
9 |
Material Type: Artigo
|
![]() |
PRIMARY ANALYSIS RESULTS OF THE SINGLE‐ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (L‐MIND)Salles, G. ; Duell, J. ; González Barca, E. ; Jurczak, W. ; Liberati, A.M. ; Nagy, Z. ; Obr, A. ; Gaidano, G. ; Andre, M. ; Kalakonda, N. ; Dreyling, M. ; Zinzani, P.L. ; Dirnberger‐Hertweck, M. ; Weirather, J. ; Ambarkhane, S. ; Maddocks, K.Hematological oncology, 2019-06, Vol.37 (S2), p.173-174 [Periódico revisado por pares]Chichester: Wiley Subscription Services, IncTexto completo disponível |
10 |
Material Type: Artigo
|
![]() |
POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R‐CHP VERSUS R‐CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCLTilly, H. ; Flowers, C. ; Friedberg, J.W. ; Herbaux, C. ; Morschhauser, F. ; Sehn, L.H. ; Sharman, J. ; Trněný, M. ; Lee, C. ; Salles, G.Hematological oncology, 2019-06, Vol.37 (S2), p.68-70 [Periódico revisado por pares]Chichester: Wiley Subscription Services, IncTexto completo disponível |